Stock comparison
Eli Lilly
LLY
Market cap
$1.01T
Sector
Healthcare
Overall winner
Eli Lilly
LLY 7–0 PFE
Pfizer
PFE
Market cap
$148.41B
Sector
Healthcare
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
LLYvsPFE
73B
55C
88A
54C
87A
47D
75B
22F
77C
31F
86A
58D
77C
54D
Side-by-side metrics
| Metric | LLY | PFE |
|---|---|---|
| Market cap | $1.01T | $148.41B |
| P/E (TTM) | 39.1x | 19.9x |
| EV/EBIT | 36.3x | 13.7x |
| ROIC (TTM) | 32.06% | 7.97% |
| Gross margin | 83.51% | 69.35% |
| Net margin | 34.98% | 11.83% |
| Revenue CAGR 5y | 23.17% | -6.33% |
| EPS CAGR 5y | 40.81% | -23.42% |
| Debt / Equity | 1.4x | 0.7x |
| Dividend yield | 0.58% | 6.58% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LLY leads on
- EPS CAGR 5y40.81%vs -23.42%+157%
- Revenue CAGR 5y23.17%vs -6.33%+127%
- Market cap$1.01Tvs $148.41B+85%
- ROIC (TTM)32.06%vs 7.97%+75%
PFE leads on
- Dividend yield6.58%vs 0.58%+91%
- EV/EBIT13.7xvs 36.3x+62%
- P/E (TTM)19.9xvs 39.1x+49%
- Debt / Equity0.7xvs 1.4x+49%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.